#USA #San Francisco #ACROBiosystems #JPMorgan #BIOSeedin

ACROBiosystems Promotes Innovation at BioSeedin's JPM Spotlight

On January 11, 2026, just ahead of the J.P. Morgan conference, San Francisco hosted the BIOSeedin Winter Innovation Partnering Summit. This important gathering served as a platform for ACROBiosystems, a key strategic partner in the biopharmaceutical industry, to engage with pharmaceutical companies, investors, and biotech firms in discussions aimed at driving innovation and forming global collaborations.

The summit, themed around the "Global Matching of Innovative Assets", was attended by over 500 delegates who passionately debated opportunities for licensing and globalization strategies. Major sponsors of the event included renowned companies such as Lilly, Roche, and Fangda Partners, reflecting the high stakes and ambitions present at the gathering.

ACROBiosystems spearheaded a networking session designed to cultivate deeper discussions with leading figures from the pharmaceutical and biotech industries. These conversations were critical in addressing the global expansion of locally developed drugs, focusing on licensing agreements, clinical development, and market access strategies.

Innovative Strategies and Global Collaboration

In a series of focused sessions, industry leaders shared insights on various pressing topics:

• - Oncology: Panelists emphasized China's unique strengths in clinical speed and platform iteration. They forecasted competitive innovations in antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and gene/cell therapies coming out of the region in the near future.

• - Cardio-Renal-Metabolic Session: Experts discussed risk mitigation strategies in clinical trials, highlighting the essential role of small biotech firms as key players in innovation. Meanwhile, larger multinationals leverage their strengths in the cardiovascular market.

• - Autoimmunity Session: Discussions revolved around the design of first-in-class (FIC) targets, offering insights into smarter deal structures, regional stratification, and global coordination aimed at accelerating value generation.

Notable senior leaders from globally recognized pharmaceutical, investment, and biotech groups facilitated and participated in these sessions. Key representatives came from firms such as Pfizer, AbbVie, Daiichi Sankyo, and Bayer, adding to the diversity of expertise presented.

Various hatcheries and biotech companies, including Adagene, EpimAb Biotherapeutics, and Innovative Cellular Therapeutics, showcased their developments in antibody technology, bi-specifics, and neurometabolic advancements during the summit, enhancing the collaborative atmosphere.

About ACROBiosystems Group

Founded in 2010 and publicly listed in 2021, ACROBiosystems Group aims to be a cornerstone of the global biopharmaceutical industry. With operations in 16 global cities, the group has fostered long-term partnerships with top pharmaceutical companies and academic institutions. Their brand ethos, "Connecting the World — Your Partner from Discovery to Clinic," mirrors their commitment to facilitating collaborations and enhancing global innovation.

The company’s comprehensive product portfolio includes recombinant proteins, kits, antibodies, and services—all backed by a rigorous quality control process from R&D to commercial production. By continuously developing new technologies and products, ACROBiosystems not only creates value for the global pharmaceutical landscape but also empowers its partners dedicated to expediting drug development and enhancing global health.

The discussions and collaborations fostered during the BIOSeedin Winter Innovation Partnering Summit underscore the vitality of global partnerships in healthcare innovation. As ACROBiosystems continues to engage with leaders across the sector, the future of biopharmaceutical collaboration looks promising.